Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT04379635 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04379635
- Sponsor
- BeiGene
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-29
- Primary completion
- 2023-08-21
- Enrollment
- 453
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.